Review article: The effect of aminosalicylates and immunomodulation on cancer risk in inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 24, Issue SUPPL. 3, 2006, Pages 64-67

  Stange, E F ^a  

^a ROBERT BOSCH HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; AMINOSALICYLIC ACID DERIVATIVE; AZATHIOPRINE; BILE ACID; MERCAPTOPURINE; MESALAZINE; PROSTAGLANDIN INHIBITOR; SALAZOSULFAPYRIDINE; URSODEOXYCHOLIC ACID;

ANTIINFLAMMATORY ACTIVITY; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; COLORECTAL CARCINOMA; CROHN DISEASE; DIAGNOSTIC PROCEDURE; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DYSPLASIA; ENTERITIS; HEALTH SURVEY; HUMAN; IMMUNOMODULATION; MEDICAL LITERATURE; META ANALYSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; ULCERATIVE COLITIS;

AMINOSALICYLIC ACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; CROHN DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES; RISK FACTORS;

EID: 33748323087     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.03063.x     Document Type: Review

References (14)

1. Eaden JA, Abrams KR, Mayberry JF. The risk of colon cancer in ulcerative colitis. Gut 2001; 48: 526-35.
2. Persson PG, Bernell O, Leijonmarck CE, Farahmand BY, Hellers G, Ahlbom A. Survival and cause-specific mortality in inflammatory bowel disease: a population-based cohort study. Gastroenterology 1996; 110: 1339-45.
3. Lynch DA, Lobo AJ, Sobala GM, Dixon MF, Axon AT. Failure of colonoscopic surveillance in ulcerative colitis. Gut 1993; 34: 1075-80.
4. Provenzale D, Kowdley KV, Arora S, Wong JB. Prophylactic colectomy or surveillance for chronic ulcerative colitis? A decision analysis. Gastroenterology 1995; 109: 1188-96.
5. Kiesslich R, Burg J, Vieth M, et al. Confocal laser endoscopy for diagnosing intraepithelial neoplasias and colorectal cancer in vivo. Gastroenterology 2004; 127: 706-13.
6. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005; 100: 1345-53.
7. van Staa TP, Card T, Logan RF, Leufkens HG. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut 2005; 54: 1573-8.
8. Lashner BA, Provencher KS, Seidner DL, Knesebeck A, Brzezinski A. The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology 1997; 112: 29-32.
9. Matula S, Croog V, Itzkowitz S, et al. Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of mercaptopurine, and MP to 6-MP. Clin Gastroenterol Hepatol 2005; 3: 1015-21.
10. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004; 126: 451-9.
11. Horn H, Preclik G, Stange EF, Ditschuneit H. Modulation of arachidonic acid metabolism by olsalazine and other aminosalicylates in leukocytes. Scand J Gastroenterol 1991; 26: 867-79.
12. Rousseaux C, Lefebvre B, Dubuquoy L, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator- activated receptor-{gamma}. J Exp Med 2005; 201: 1205-15.
13. Matthiessen MW, Pedersen G, Albrektsen T, Adamsen S, Fleckner J, Brynskov J. Peroxisome proliferator-activated receptor expression and activation in normal human colonic epithelial cells and tubular adenomas. Scand J Gastroenterol 2005; 40: 198-205.
14. Shimada T, Kojima K, Yoshiura K, Hiraishi H, Terano A. Characteristics of the peroxisome proliferator activated receptor gamma (PPARgamma) ligand induced apoptosis in colon cancer cells. Gut 2002; 50: 658-64.